Growth hormone
Increase · large
Stimulates pituitary GH release
Literature evidence
Compound library
Vivy evidence dossier
CJC-1295
Also indexed as GRF 1-29, CJC-1295 with DAC
T3Peptides
Read this entry as context, not instruction.
Evidence labels describe the material available in this reference entry. They do not establish that a compound is appropriate, effective, or safe for you. Inclusion is not a recommendation to use it.
Reference context
Pharmacokinetic context
Half-life8 hr
This field summarizes the library record. Half-life can vary with formulation, indication, and individual clinical context.
Observed relationships
Biomarker context
IGF-1
Increase · large
GH/IGF-1 axis activation
Literature evidence
IGFBP-3
Increase · moderate
GH-mediated binding proteins
Literature evidence
Keep in view
Safety discussion points
CJC-1295 is a Growth Hormone Releasing Hormone (GHRH) analog with a Drug Affinity Complex (DAC) that extends half-life. Promotes GH and IGF-1 secretion. Not FDA-approved.
Keep the reference close
Track CJC-1295 in context.
Hey Vivy helps you organize protocols and review change over time. It does not diagnose, prescribe, or replace qualified care.